UniProt ID | ISCU_HUMAN | |
---|---|---|
UniProt AC | Q9H1K1 | |
Protein Name | Iron-sulfur cluster assembly enzyme ISCU, mitochondrial | |
Gene Name | ISCU | |
Organism | Homo sapiens (Human). | |
Sequence Length | 167 | |
Subcellular Localization |
Isoform 1: Mitochondrion . Isoform 2: Cytoplasm. Nucleus . |
|
Protein Description | Scaffold protein for the de novo synthesis of iron-sulfur (Fe-S) clusters within mitochondria, which is required for maturation of both mitochondrial and cytoplasmic [2Fe-2S] and [4Fe-4S] proteins. [PubMed: 11060020 First, a [2Fe-2S] cluster is transiently assembled on the scaffold protein ISCU. In a second step, the cluster is released from ISCU, transferred to a glutaredoxin GLRX5, followed by the formation of mitochondrial [2Fe-2S] proteins, the synthesis of [4Fe-4S] clusters and their target-specific insertion into the recipient apoproteins. Cluster assembly on ISCU depends on the function of the cysteine desulfurase complex NFS1-LYRM4/ISD11, which serves as the sulfur donor for cluster synthesis, the iron-binding protein frataxin as the putative iron donor, and the electron transfer chain comprised of ferredoxin reductase and ferredoxin, which receive their electrons from NADH (By similarity] | |
Protein Sequence | MAAAGAFRLRRAASALLLRSPRLPARELSAPARLYHKKVVDHYENPRNVGSLDKTSKNVGTGLVGAPACGDVMKLQIQVDEKGKIVDARFKTFGCGSAIASSSLATEWVKGKTVEEALTIKNTDIAKELCLPPVKLHCSMLAEDAIKAALADYKLKQEPKKGEAEKK | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
7 (in isoform 2) | Phosphorylation | - | 8.06 | 25404012 | |
11 (in isoform 2) | Phosphorylation | - | 38.81 | 20068231 | |
12 (in isoform 2) | Phosphorylation | - | 10.19 | 20068231 | |
14 | Phosphorylation | FRLRRAASALLLRSP HHHHHHHHHHHHCCC | 20.61 | 19664994 | |
18 (in isoform 2) | Phosphorylation | - | 5.46 | 20068231 | |
20 | Phosphorylation | ASALLLRSPRLPARE HHHHHHCCCCCCHHH | 17.84 | 26055452 | |
29 | Phosphorylation | RLPARELSAPARLYH CCCHHHHCCCCHHHC | 27.70 | 30266825 | |
29 (in isoform 2) | Ubiquitination | - | 27.70 | 21890473 | |
32 (in isoform 2) | Ubiquitination | - | 17.52 | 21890473 | |
43 | Phosphorylation | HKKVVDHYENPRNVG CHHHHCCCCCCCCCC | 16.97 | 25884760 | |
51 | Phosphorylation | ENPRNVGSLDKTSKN CCCCCCCCCCCCCCC | 29.16 | - | |
54 | Ubiquitination | RNVGSLDKTSKNVGT CCCCCCCCCCCCCCC | 61.05 | 21890473 | |
54 (in isoform 1) | Ubiquitination | - | 61.05 | 21890473 | |
57 (in isoform 2) | Ubiquitination | - | 61.97 | 21890473 | |
57 | Ubiquitination | GSLDKTSKNVGTGLV CCCCCCCCCCCCCCC | 61.97 | 21890473 | |
57 (in isoform 1) | Ubiquitination | - | 61.97 | 21890473 | |
66 (in isoform 2) | Ubiquitination | - | 4.88 | 21890473 | |
69 | Glutathionylation | GLVGAPACGDVMKLQ CCCCCCCCCCEEEEE | 4.68 | 22555962 | |
73 | Sulfoxidation | APACGDVMKLQIQVD CCCCCCEEEEEEEEC | 4.22 | 21406390 | |
82 (in isoform 1) | Ubiquitination | - | 62.13 | 21890473 | |
82 | Ubiquitination | LQIQVDEKGKIVDAR EEEEECCCCCEEEEE | 62.13 | 21890473 | |
82 | 2-Hydroxyisobutyrylation | LQIQVDEKGKIVDAR EEEEECCCCCEEEEE | 62.13 | - | |
87 (in isoform 2) | Ubiquitination | - | 35.18 | 21890473 | |
91 (in isoform 1) | Ubiquitination | - | 37.07 | 21890473 | |
91 | Ubiquitination | KIVDARFKTFGCGSA CEEEEEEEEECCCHH | 37.07 | 21890473 | |
92 | Phosphorylation | IVDARFKTFGCGSAI EEEEEEEEECCCHHH | 23.65 | 21406692 | |
96 (in isoform 2) | Ubiquitination | - | 22.08 | 21890473 | |
97 | Phosphorylation | FKTFGCGSAIASSSL EEEECCCHHHHCCHH | 22.15 | 18669648 | |
101 | Phosphorylation | GCGSAIASSSLATEW CCCHHHHCCHHCHHH | 17.85 | 18669648 | |
102 | Phosphorylation | CGSAIASSSLATEWV CCHHHHCCHHCHHHH | 21.98 | 18669648 | |
103 | Phosphorylation | GSAIASSSLATEWVK CHHHHCCHHCHHHHC | 21.37 | 21406692 | |
106 | Phosphorylation | IASSSLATEWVKGKT HHCCHHCHHHHCCCC | 35.36 | 21406692 | |
112 | Ubiquitination | ATEWVKGKTVEEALT CHHHHCCCCHHHHHH | 43.62 | 21890473 | |
112 (in isoform 1) | Ubiquitination | - | 43.62 | 21890473 | |
121 | Ubiquitination | VEEALTIKNTDIAKE HHHHHHCCCCHHHHH | 48.86 | 21890473 | |
121 (in isoform 1) | Ubiquitination | - | 48.86 | 21890473 | |
122 (in isoform 2) | Ubiquitination | - | 38.85 | 21890473 | |
127 | Acetylation | IKNTDIAKELCLPPV CCCCHHHHHHCCCCC | 52.10 | 25038526 | |
147 | Ubiquitination | MLAEDAIKAALADYK HHHHHHHHHHHHHHH | 29.36 | 21890473 | |
147 (in isoform 1) | Ubiquitination | - | 29.36 | 21890473 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
14 | S | Phosphorylation | Kinase | MTOR | P42345 | PSP |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of ISCU_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of ISCU_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
NUP62_HUMAN | NUP62 | physical | 25416956 | |
NECA2_HUMAN | NECAB2 | physical | 25416956 | |
BANP_HUMAN | BANP | physical | 25416956 | |
ATRAP_HUMAN | AGTRAP | physical | 25416956 | |
LNX1_HUMAN | LNX1 | physical | 25416956 | |
K1C40_HUMAN | KRT40 | physical | 25416956 | |
FAM9B_HUMAN | FAM9B | physical | 25416956 | |
CC172_HUMAN | CCDC172 | physical | 25416956 | |
HSC20_HUMAN | HSCB | physical | 24573684 | |
NFS1_HUMAN | NFS1 | physical | 24573684 | |
NECA2_HUMAN | NECAB2 | physical | 21516116 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
OMIM Disease | ||||||
255125 | Myopathy with exercise intolerance Swedish type (MEIS) | |||||
Kegg Drug | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14, VARIANT VAL-12, ANDMASS SPECTROMETRY. | |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14, AND MASSSPECTROMETRY. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14, AND MASSSPECTROMETRY. |